Clinical Performance of Three Commercial Molecular Diagnostic Assays for the Detection of Fluoroquinolone Resistance-Associated Mutations in Mycoplasma genitalium

1st Author: Gardette M, Hénin N, Le Roy C, et al. (2022)

Key point:
In the absence of Ser83Ile (G248T) and mutations at position at 83 and 87 in parC, the probability of moxifloxacin cure of macrolide-resistant Mycoplasma genitalium was 96.4% and 97.8%, respectively. This suggests that selection of antibiotics via testing the existence of parC mutation using Allplex™ MG & MoxiR Assay is essential in increasing the treatment efficiency of Mycoplasma genitalium.